Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin
National, Phase III, Radomized, Double-Blind, Double -Dummy, Controlled, Parallel to Evaluate Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) Soft Gel Capsules in the Control of Acute Vertigo Symphtoms From Peripheral Origin
Sponsor: Apsen Farmaceutica S.A.
Listed as NCT02112578, this PHASE3 trial focuses on Vertigo, Peripheral and remains completed. Sponsored by Apsen Farmaceutica S.A., it has been updated 7 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Jan 2021 — Mar 2023 [monthly]
Unknown Status PHASE3
-
Jan 2019 — Jan 2021 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2019 [monthly]
Recruiting PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Apsen Farmaceutica S.A.
For direct contact, visit the study record on ClinicalTrials.gov .